Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial

Stone, Gregg W.; Ellis, Stephen G.; Gori, Tommaso; Metzger, D. Christopher; Stein, Bernardo; Erickson, Matthew; Torzewski, Jan; Williams, Jerome; Lawson, William; Broderick, Thomas M.; Kabour, Ameer; Piegari, Guy; Cavendish, Jeffrey J.; Bertolet, Barry D.; Choi, James W.; Marx, Steven O.; Généreux, Philippe; Kereiakes, Dean J.; Investigators, Absorb Iv

doi:10.1016/s0140-6736(18)32283-9

Cited by 113 publications

(65 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These composites also showed interesting mechanical properties and therefore were proposed as suitable for implantable biopolymers. The performance of PLA drug eluting stents was found as positive in a one-year clinical trial [186], but they also showed limitations when implanted in a suboptimal way [187]. Given problems in recoil of the polymeric stents and device induced thrombosis, the Nobori ® developers opted for a solution that combined chromium-platinum stents with a PLA coating that could elute anti-restenosis drugs [188].…”

Section: Bioplastics Polymers As Implants In Vivomentioning

confidence: 99%

Recent Advances in Bioplastics: Application and Biodegradation

et al. 2020

View full text Add to dashboard Cite

The success of oil-based plastics and the continued growth of production and utilisation can be attributed to their cost, durability, strength to weight ratio, and eight contributions to the ease of everyday life. However, their mainly single use, durability and recalcitrant nature have led to a substantial increase of plastics as a fraction of municipal solid waste. The need to substitute single use products that are not easy to collect has inspired a lot of research towards finding sustainable replacements for oil-based plastics. In addition, specific physicochemical, biological, and degradation properties of biodegradable polymers have made them attractive materials for biomedical applications. This review summarises the advances in drug delivery systems, specifically design of nanoparticles based on the biodegradable polymers. We also discuss the research performed in the area of biophotonics and challenges and opportunities brought by the design and application of biodegradable polymers in tissue engineering. We then discuss state-of-the-art research in the design and application of biodegradable polymers in packaging and emphasise the advances in smart packaging development. Finally, we provide an overview of the biodegradation of these polymers and composites in managed and unmanaged environments.

show abstract

Section: Bioplastics Polymers As Implants In Vivomentioning

confidence: 99%

Recent Advances in Bioplastics: Application and Biodegradation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…10 papers eventually met all inclusion criteria [8][9][10][11][12][13][14][15][16][17]. The other 352 articles were excluded due to duplication, article types, irrelevant studies, no control groups, incomplete data or comparisons.…”

Section: Search Resultsmentioning

confidence: 99%

Bioresorbable vascular stents and drug-eluting stents in treatment of coronary heart disease: a meta-analysis

Ni¹,

Chen²,

Luo³

et al. 2020

J Cardiothorac Surg

View full text Add to dashboard Cite

Objective: To compare the efficacy and safety of bioresorbable vascular stents (BVS) and drug-eluting stents (DES) in coronary heart disease. Methods: The full text of clinical studies involving BVS and DES was retrieved in PubMed, Springer, EMBASE, Wiley-Blackwell, and Chinese Journal Full-text Database. Review Manager 5.3 was used for meta-analysis to evaluate the risk of target lesion failure, stent thrombosis and cardiac death in BVS and DES. Results: Finally, 10 studies with 6383 patients were included in the meta-analysis. Compared with DES group, BVS group had significantly increased risk of target lesion failure (OR = 1.46, 95%CI 1.20-1.79, P = 0.0002; P Heterogeneity = 0.68, I 2 = 0%), stent thrombosis (OR = 2.70, 95%CI 1.57-4.66, P = 0.0003; P Heterogeneity = 1.00, I 2 = 0%) and cardiac death (OR = 2.19, 95%CI 1.17-4.07, P = 0.01; P Heterogeneity = 0.93, I 2 = 0%). Conclusion: This study shows that DES is a safer treatment than BVS for coronary revascularization.

show abstract

“…Journal of Translational Medicine *Correspondence: tousek@email.cz † Viktor Kočka and Petr Toušek contributed equally to this manuscript 1 Cardiocenter, Third Faculty of Medicine, Charles University and University Hospital Kralovské Vinohrady, Šrobárova 50, Prague 10 100 34, Czech Republic Full list of author information is available at the end of the article Page 2 of 9 Kočka et al J Transl Med (2020) 18:33 studies [4]. However, the recently published largest randomized ABSORB IV study of Absorb ™ BRS (not included in the above cited meta-analyses) with optimal implantation technique and careful patient selection resulted in non-inferior target lesion failure at 1 year [5]. Thus, the discussion about safety and effectivity of BRS technology continues.…”

Section: Open Accessmentioning

confidence: 99%

Bioresorbable scaffold implantation in STEMI patients: 5 years imaging subanalysis of PRAGUE-19 study

et al. 2020

View full text Add to dashboard Cite

Background: Bioresorbable scaffold (BRS) Absorb ™ clinical use has been stopped due to higher rate of device thrombosis. Scaffold struts persist longer than 2 years in the vessel wall. Second generation devices are being developed. This study evaluates long-term invasive imaging in STEMI patients.Methods: PRAGUE-19 study is an academic study enrolling consecutive STEMI patients with intention to implant Absorb ™ BRS. A total of 83 STEMI patients between December 2012 and March 2014 fulfilled entry criteria. Coronary angiography and optical coherence tomography at 5 year follow-up was performed in 25 patients.Results: Primary combined clinical endpoint (death, myocardial infarction or target vessel revascularization) occurred in 12.6% during the five-year follow-up with overall mortality 6.3%. Definite scaffold thrombosis occurred in 2 patients in the early phase after BRS implantation. Quantitative coronary angiography after 5 years demonstrated low late lumen loss of 0.11 ± 0.35 mm with binary restenosis rate of 0%. Optical coherence tomography demonstrated complete resorption of scaffold struts and mean lumen diameter of 3.25 ± 0.30 and 3.22 ± 0.49 (P = 0.73) at baseline and after 5 years, respectively. Three patients developed small coronary artery aneurysm in the treated segment. Conclusion:Invasive imaging results 5 years after BRS implantation in STEMI showed complete resorption of scaffold struts and stable lumen vessel diameter.Trial registration ISRCTN43696201 (retrospectivelly registred, June 7th, 2019). https ://www.isrct n.com/ISRCT N4369 6201.

show abstract

Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial

Cited by 113 publications

References 23 publications

Recent Advances in Bioplastics: Application and Biodegradation

Recent Advances in Bioplastics: Application and Biodegradation

Bioresorbable vascular stents and drug-eluting stents in treatment of coronary heart disease: a meta-analysis

Bioresorbable scaffold implantation in STEMI patients: 5 years imaging subanalysis of PRAGUE-19 study

Contact Info

Product

Resources

About